Pipeline

"We develop degrader pipelines with a robust scientific rationale and a clear market goal"

• Despite the challenges, our focus lies not on fast-following targets but on previously undruggable or unconquered targets with the potential to be first-in-class drugs.
• We decide to pursue a specific degrader pipeline only when we determine that the TPD modality is the best option over other drug modalities for addressing a specific disease-causing protein, considering its related biology and pathology.